[Effect of dexmedetomidine on perioperative inflammatory response and cellular immune in patients undergoing radical operation of thoracoscopic lung cancer].

To evaluate the effect of dexemdetomidine on perioperative inflammatory response and cellular immune in patients undergoing radical operation of thoracoscopic lung cancer. One hundred and twenty patients undergone radical operation of thoracoscopic lung cancer were randomly divided into control group(group B) and dexemdetomidine group(group A), 60 patients in each group. They were all implemented one-lung ventilation. In group A, dexmedetomidine at a loading dose of 1.0 μg/kg was intravenously infused starting from 20 min before anesthesia induction, followed by continuous infusion of 0.5 μg·kg(-1)·h(-1) until 20 min before the end of operation. The equal volume of normal saline was given in group B. venous blood samples were collected for determination of the serum concentrations of TNF-α, IL-6 and IL-8. peripheral blood T-lymphocyte subsets(CD(3)(+), CD(4)(+), CD(8)(+), CD(4)(+)/CD(8)(+)) and NK cell were also detected at 30 min before anesthesia induction(T(0)), at the end of operation(T(1)), 12 h after operation(T(2)) and 24 h after operation(T(3)). Compared with the T(0, )the plasma concentration of TNF-α , IL-6 and IL-8 were increased(<0.05). The levels of CD(3)(+) and CD(4)(+), CD(4)(+)/CD(8)(+) ratio and NK cells were decreased in both groups at T(1)-T(3)(<0.05). Compared with group B, the plasma concentration of TNF-α , IL-6 and IL-8 were decreased more obviously in group A(<0.05). The levels of CD(3)(+) and CD(4)(+), CD(4)(+)/CD(8)(+) ratio and NK cells were significantly increased in group A at T(1)-T(3)(<0.05). Dexemdetomidine can decrease perioperative inflarnmatory response and improve cellular immune function in the patients undergoing radical operation of thoracoscopic lung cancer.